Welcome to our dedicated page for Quantum BioPharma news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum BioPharma stock.
Quantum BioPharma Ltd (QNTM) is a biopharmaceutical innovator developing therapies for neurodegenerative, neuropsychiatric, and inflammatory disorders. This page aggregates official news and press releases about the company’s clinical advancements, strategic investments, and market-related developments.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and strategic financial decisions, including partnerships or legal initiatives impacting shareholder value. The curated content spans research breakthroughs, intellectual property updates, and balanced coverage of both pharmaceutical R&D and complementary investment activities.
All content is sourced directly from company communications to ensure accuracy. Visitors can expect coverage of FDA trial phases, compound licensing deals, and portfolio management decisions from Quantum BioPharma’s dual operational segments. Bookmark this page for efficient tracking of material events affecting QNTM’s trajectory in the biotech sector.
Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), a licensee of Quantum BioPharma (NASDAQ: QNTM), has taken significant steps toward a potential IPO by hiring MNP LLP as its new PCAOB-registered audit firm effective May 20, 2025. This follows the company's February 2025 announcement of retaining a New York investment bank for capital raising and IPO exploration.
The company, known for its unbuzzd™ beverage that accelerates alcohol metabolism and reduces hangover symptoms, is led by CEO John Duffy, former Coca-Cola VP, and Board Co-Chair Gerry David, former CEO of Celsius Holdings. The company also completed a name change to Unbuzzd Wellness Inc. effective May 23, 2025, with new CUSIP (90429T100) and ISIN (CA90429T1003) numbers.
Quantum BioPharma (NASDAQ: QNTM) has received Human Ethics Review Committee approval in Australia for a Phase 2 clinical trial of FSD202, targeting nociplastic pain in patients with Idiopathic Mast Cell Activation Syndrome (MCAS). The trial will be a randomized, double-blind, placebo-controlled study involving 60 patients who will receive either FSD202 or placebo twice daily for 56 days.
The study's primary endpoint is measuring the decrease in average daily pain intensity from baseline to Day 28. FSD202, containing ultra-micronized palmitoylethanolamide (PEA), aims to address inflammatory diseases, particularly MCAS, which causes multisystem symptoms and chronic widespread musculoskeletal pain. Currently, MCAS has no known cure, and patients suffer from repeated anaphylactic symptoms and chronic pain.
[ "Phase 2 trial approval received from ethics committee, advancing clinical development pipeline", "Trial targets MCAS, which currently has no cure, representing a significant market opportunity", "FSD202 has potential applications beyond MCAS in other inflammatory diseases", "Well-designed trial with clear endpoints and controlled study parameters" ]Quantum BioPharma (NASDAQ: QNTM) has announced a partnership with BitGo Trust Company to manage and store its cryptocurrency holdings, including Bitcoin, Solana, XRP, and DOGE coins. BitGo will provide institutional-grade custody services featuring multi-signature wallets and 100% cold storage technology to protect against theft, loss, and unauthorized access.
The partnership aims to enhance security and compliance for Quantum's crypto assets, with BitGo offering an insurance policy as an additional security layer. CEO Zeeshan Saeed emphasized that this collaboration aligns with the company's security and compliance priorities as a public company.
Quantum BioPharma (NASDAQ: QNTM) has signed an agreement with a global pharmaceutical contract research organization to prepare an Investigational New Drug (IND) application for Lucid-21-302 (Lucid-MS), targeting submission to the FDA in Q4 2025. The successful IND application will enable the company to proceed with Phase 2 trials for multiple sclerosis treatment.
Lucid-21-302 is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action. This patented New Chemical Entity has demonstrated ability in preclinical models to prevent demyelination, a known cause of MS and other neurodegenerative diseases affecting the myelin sheath around nerve fibers.
Quantum BioPharma (NASDAQ: QNTM) has expanded its cryptocurrency investment by purchasing an additional USD $1 million worth of Bitcoin and other cryptocurrencies, bringing its total digital asset investment to USD $4.5 million. The purchase, approved by the Board of Directors, is part of the company's strategic initiative to hedge against the Canadian dollar and generate returns for shareholders. The company has established infrastructure to accept cryptocurrency-based financing and execute other transactions, with all digital assets being held by a compliant custodian. Quantum BioPharma maintains flexibility to adjust its cryptocurrency holdings based on market conditions, while ensuring compliance with financial and audit regulations.
Quantum BioPharma (NASDAQ: QNTM) has announced its participation in two upcoming investor conferences in May 2025. The company's Head of Finance and M&A, Jason Sawyer, will attend the Sidoti Micro-Cap Conference on May 21 and the A.G.P. Virtual Healthcare Conference on May 22.
At the Sidoti conference, Mr. Sawyer will deliver a webcast presentation from 9:15-9:45 AM ET and conduct one-on-one meetings with institutional investors. The following day at the A.G.P. conference, he will participate in virtual one-on-one meetings with investors. Interested parties can schedule meetings through conference representatives or by contacting QNTM@mzgroup.us.
Quantum BioPharma (NASDAQ: QNTM) has completed the dosing phase of 90-day oral toxicity and toxicokinetic studies for its Multiple Sclerosis drug candidate Lucid-21-302 (Lucid-MS). These studies are crucial for supporting an upcoming Investigational New Drug (IND) application with the US FDA, which the company aims to submit by the end of 2025. The completion of these toxicity studies marks a significant step toward initiating a Phase 2 trial for Lucid-MS, which is being developed as a first-in-class treatment for Multiple Sclerosis patients.
Quantum BioPharma (NASDAQ: QNTM) has filed an amended complaint in the U.S. District Court for the Southern District of New York against CIBC World Markets and RBC Dominion Securities, seeking damages exceeding $700 million USD. The lawsuit alleges that between January 2020 and August 2024, the defendants engaged in market manipulation through "spoofing" techniques, violating multiple sections of the Securities Exchange Act of 1934.
The company's stock, which traded above $460 USD per share in January 2020 with a market cap approaching $1 billion, was allegedly artificially depressed by hundreds of spoofing incidents. Law firms Christian Attar and Freedman Normand Friedland LLP are handling the case on a contingency basis, eliminating material financial pressure on Quantum BioPharma for legal costs.
FAQ
What is the current stock price of Quantum BioPharma (QNTM)?
What is the market cap of Quantum BioPharma (QNTM)?
